(ZTS) Zoetis - NYSE
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 33.358m USD | Total Return: -50.6% in 12m
Avg Turnover: 546M
EPS Trend: 98.1%
Qual. Beats: -1
Rev. Trend: 96.0%
Qual. Beats: -1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Zoetis Inc. is a global leader in the animal health industry, specializing in the development and commercialization of medicines, vaccines, and diagnostic tools for both companion animals and livestock. Its product portfolio spans parasiticides, dermatology treatments, and precision health solutions, serving a diverse customer base of veterinarians, livestock producers, and pet owners.
The company operates within a specialized pharmaceutical sub-sector characterized by high barriers to entry and long product lifecycles, as animal health products are typically purchased out-of-pocket rather than through third-party payers. Zoetis maintains a diversified revenue stream by balancing high-margin companion animal services with essential livestock productivity solutions. For a deeper look into these fundamental drivers, consider reviewing the detailed metrics on ValueRay.
Headquartered in New Jersey, Zoetis continues to expand its technological footprint through R&D collaborations and advancements in genetic testing and point-of-care diagnostics. This integrated business model allows the firm to capture value across the entire continuum of animal care, from prevention and detection to treatment.
- Companion animal parasiticides and dermatology products drive high-margin revenue growth
- Monoclonal antibody launches for feline and canine osteoarthritis expand total addressable market
- Livestock segment performance fluctuates based on global commodity prices and disease outbreaks
- Direct-to-consumer marketing spend and R&D investment impact short-term operating margins
- Diagnostic platform adoption increases recurring revenue through hardware and consumable sales synergies
| Net Income: 2.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -2.08 > 1.0 |
| NWC/Revenue: 46.49% < 20% (prev 26.84%; Δ 19.66% < -1%) |
| CFO/TA 0.18 > 3% & CFO 2.72b > Net Income 2.64b |
| Net Debt (7.49b) to EBITDA (4.03b): 1.86 < 3 |
| Current Ratio: 3.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (422.4m) vs 12m ago -5.71% < -2% |
| Gross Margin: 70.75% > 18% (prev 69.48%; Δ 1.27% > 0.5%) |
| Asset Turnover: 65.01% > 50% (prev 65.87%; Δ -0.85% > 0%) |
| Interest Coverage Ratio: 14.70 > 6 (EBIT TTM 3.54b / Interest Expense TTM 241.0m) |
| A: 0.29 (Total Current Assets 6.47b - Total Current Liabilities 2.05b) / Total Assets 15.2b |
| B: 0.94 (Retained Earnings 14.2b / Total Assets 15.2b) |
| C: 0.24 (EBIT TTM 3.54b / Avg Total Assets 14.6b) |
| D: 0.27 (Book Value of Equity 3.23b / Total Liabilities 11.9b) |
| Altman-Z'' = 6.88 = AAA |
| DSRI: 1.08 (Receivables 1.51b/1.36b, Revenue 9.51b/9.29b) |
| GMI: 0.98 (GM 69.48% / 70.75%) |
| AQI: 0.95 (AQ_t 0.31 / AQ_t-1 0.32) |
| SGI: 1.02 (Revenue 9.51b / 9.29b) |
| TATA: -0.00 (NI 2.64b - CFO 2.72b) / TA 15.2b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of June 16, 2026, the stock is trading at USD 79.95 with a total of 4,415,584 shares traded.
Over the past week, the price has changed by +1.43%,
over one month by +7.72%,
over three months by -32.04% and
over the past year by -50.61%.
Zoetis has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy ZTS.
- StrongBuy: 9
- Buy: 3
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 124.6 | 55.8% |
P/E Trailing = 13.0443
P/E Forward = 11.6279
P/S = 3.4999
P/B = 10.318
P/EG = 1.9071
Revenue TTM = 9.51b USD
EBIT TTM = 3.54b USD
EBITDA TTM = 4.03b USD
Long Term Debt = 9.04b USD (from longTermDebt, last quarter)
Short Term Debt = 53.0m USD (from shortTermDebt, last fiscal year)
Debt = 9.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 193.0m
Net Debt = 7.49b USD (calculated: Debt 9.43b - CCE 1.94b)
Enterprise Value = 40.8b USD (33.4b + Debt 9.43b - CCE 1.94b)
Interest Coverage Ratio = 14.70 (Ebit TTM 3.54b / Interest Expense TTM 241.0m)
EV/FCF = 19.12x (Enterprise Value 40.8b / FCF TTM 2.14b)
FCF Yield = 5.23% (FCF TTM 2.14b / Enterprise Value 40.8b)
FCF Margin = 22.46% (FCF TTM 2.14b / Revenue TTM 9.51b)
Net Margin = 27.79% (Net Income TTM 2.64b / Revenue TTM 9.51b)
Gross Margin = 70.75% ((Revenue TTM 9.51b - Cost of Revenue TTM 2.78b) / Revenue TTM)
Gross Margin QoQ = 71.66% (prev 68.87%)
Tobins Q-Ratio = 2.70 (Enterprise Value 40.8b / Total Assets 15.2b)
Interest Expense / Debt = 2.56% (Interest Expense 241.0m / Debt 9.43b)
Taxrate = 20.10% (665.0m / 3.31b)
NOPAT = 2.83b (EBIT 3.54b * (1 - 20.10%))
Current Ratio = 3.15 (Total Current Assets 6.47b / Total Current Liabilities 2.05b)
Debt / Equity = 2.92 (Debt 9.43b / totalStockholderEquity, last quarter 3.23b)
Debt / EBITDA = 1.86 (Net Debt 7.49b / EBITDA 4.03b)
Debt / FCF = 3.51 (Net Debt 7.49b / FCF TTM 2.14b)
Total Stockholder Equity = 4.23b (last 4 quarters mean from totalStockholderEquity)
RoA = 18.07% (Net Income 2.64b / Total Assets 15.2b)
RoE = 62.41% (Net Income TTM 2.64b / Total Stockholder Equity 4.23b)
RoCE = 26.68% (EBIT 3.54b / Capital Employed (Equity 4.23b + L.T.Debt 9.04b))
RoIC = 22.33% (NOPAT 2.83b / Invested Capital 12.7b)
WACC = 5.42% (E(33.4b)/V(42.8b) * Re(6.37%) + D(9.43b)/V(42.8b) * Rd(2.56%) * (1-Tc(0.20)))
Discount Rate = 6.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -100.00 | Cagr: -3.73%
[DCF] Terminal Value 74.53% ; FCFF base≈2.19b ; Y1≈2.09b ; Y5≈1.98b
[DCF] Fair Price = 56.49 (EV 31.2b - Net Debt 7.49b = Equity 23.7b / Shares 419.2m; r=8.35% [WACC [floored]]; 5y FCF grow -6.36% → 2.50% )
EPS Correlation: 98.14 | EPS CAGR: 8.57% | SUE: -4.0 | # QB: -1
Revenue Correlation: 96.00 | Revenue CAGR: 5.56% | SUE: -1.16 | # QB: -1
EPS current Quarter (2026-06-30): EPS=1.86 | Chg30d=-1.96% | Revisions=-47% | Analysts=13
EPS next Quarter (2026-09-30): EPS=1.85 | Chg30d=+0.32% | Revisions=+14% | Analysts=12
EPS current Year (2026-12-31): EPS=6.90 | Chg30d=-1.89% | Revisions=-76% | GrowthEPS=+7.6% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=7.42 | Chg30d=-1.97% | Revisions=-76% | GrowthEPS=+7.7% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: -76%